Robert DiPaola, Stephen Gruber, and Candace Johnson named to AACI Board of Directors

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

ROBERT DIPAOLA, STEPHEN GRUBER and CANDACE JOHNSON were elected to the board of directors of the Association of American Cancer Institutes. Their three-year terms will begin Oct. 25, during the annual meeting of the AACI and the Cancer Center Administrators Forum in Washington, D.C.

DiPaola is director of the Rutgers Cancer Institute of New Jersey. He has held multiple local and national positions including the founding director and program leader of the Prostate Cancer Center at the Cancer Institute of New Jersey; national chairman of the Genitourinary Committee of the Eastern Oncology Cooperative Group; chief of Medical Oncology at Robert Wood Johnson Medical School; and was appointed as director of the CINJ in 2008.

Gruber was appointed director of the USC Norris Comprehensive Cancer Center in 2011. He is a professor of medicine and preventive medicine, and holds the H. Leslie and Elaine S. Hoffman Cancer Research Chair at the University of Southern California. Prior to his appointment at USC Norris, Gruber was associate director of cancer prevention and control at the University of Michigan Comprehensive Cancer Center.

As president and chief executive officer of Roswell Park Cancer Institute, Johnson oversees all cancer research, patient care, and NCI core funding. Johnson also serves as the Wallace Family Chair in Translational Research and as a professor of oncology. Prior to her appointment, Johnson was deputy director of the institute and also chair of the Department of Pharmacology and Therapeutics for more than a decade.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login